What FreedomFest 2026 Revealed About America’s Innovation Conversion Rate
America’s innovation conversion rate, not its supply of ideas, is the number I could not stop thinking about on the drive home from Las Vegas. In early July I served as an investor judge at FreedomFest’s Principled Business Pitch Competition’s first round. Twenty-two founders with ninety seconds each to move from round one into the…
Read MoreThe $81 Billion Bet: Rethinking Merger Value Creation
The proposed $81 billion Paramount–Warner Bros. Discovery merger has been framed around one headline number: $6 billion in projected synergies. But does synergy alone create enterprise value? This article argues that financial models measure outcomes—not the structural alignment that determines long-term success. By examining the deal through the EVCR lens, it explores why durable merger…
Read MoreIndustry Is Not Destiny: What the Best Value Creators Do Differently
BCG’s latest Value Creators rankings reveal a dramatic shift in industry leaders, but the real story isn’t about sectors—it’s about systems. While macro trends influence performance, the companies that consistently outperform are those with disciplined execution, aligned leadership, operational excellence, and a clear value creation strategy. This article explores why industry is not destiny, how…
Read MoreThe Stellantis Turnaround Is Real, But They Shouldn’t Have Needed One.
Stellantis’ turnaround is beginning to show promise, but the more important lesson is how the company allowed value to erode long before the financial damage became obvious. This article traces the pattern from structural drift to operating breakdown and, finally, financial decline, showing how pricing, inventory, dealer incentives, quality, and product strategy were all symptoms…
Read MoreValue Creation Moves to the Front of the Private Equity Thesis
Private equity firms are investing in operational improvement earlier than ever, but is acting sooner enough? Drawing on new industry research, this article argues that while KPIs, AI, and operating partners all play important roles, they are not substitutes for structural diagnosis. Financial results are often the last indicators to change—long after value has already begun to erode. The real advantage lies in identifying the conditions that create or destroy enterprise value before they appear in the numbers, turning value creation from a reactive exercise into a disciplined, system-wide capability.
Read MoreInnovation-Insights-2023-Media-Kit
Everyone’s life has been touched in some way by cancer. Today, some 1 million Americans are newly diagnosed with cancer and approximately 12M are living with cancer …. and most are unaware of their testing, treatment, and clinical trial options at the time they’re diagnosed
Read MoreSwellter LLC.
Everyone’s life has been touched in some way by cancer. Today, some 1 million Americans are newly diagnosed with cancer and approximately 12M are living with cancer ….and most are unaware of their testing, treatment, and clinical trial options at the time they’re diagnosed.
Read MoreSimplSEQ
SimplSeq has developed a proprietary process to prepare biological samples for next generation genomic sequencing processing that will save thousands of labs a great deal of time and expense.
Read MoreParthen, Inc.
Parthen, Inc. was formed in 2021 to utilize advances in genomic sequencing and telehealth technologies in order to provide a patient-centered approach to precision cancer care.
Read More